Liquidia Corp
NASDAQ:LQDA
Liquidia Corp
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
Strong Launch: YUTREPIA’s first full quarter exceeded expectations, with rapid uptake and positive real-world feedback from patients and physicians.
Revenue & Profitability: Net product sales reached $51.7 million, and Liquidia achieved profitability on an adjusted EBITDA basis much sooner than previously guided.
High Conversion Rate: About 85% of YUTREPIA referrals converted to active patient starts, a strong indicator of demand and commercial execution.
Payer Access: Contracts were signed with the three major commercial payers, and new-to-market formulary blocks are being removed, supporting broader access.
Indication Expansion: The majority of prescriptions are for PAH, but PH-ILD usage is growing steadily; clinical plans target further expansion into IPF and PPF.
Litigation Uncertainty: The outcome and timing of ongoing litigation with United Therapeutics remain uncertain, with potential remedies ranging from royalties to label changes.
